[go: up one dir, main page]

EP3346912A4 - Verfahren und system für mikrobiom-derivierte diagnostika und therapeutika für erkrankungen im zusammenhang mit zerebro-kraniofazialer gesundheit - Google Patents

Verfahren und system für mikrobiom-derivierte diagnostika und therapeutika für erkrankungen im zusammenhang mit zerebro-kraniofazialer gesundheit Download PDF

Info

Publication number
EP3346912A4
EP3346912A4 EP16845218.3A EP16845218A EP3346912A4 EP 3346912 A4 EP3346912 A4 EP 3346912A4 EP 16845218 A EP16845218 A EP 16845218A EP 3346912 A4 EP3346912 A4 EP 3346912A4
Authority
EP
European Patent Office
Prior art keywords
cerebro
microbiome
therapeutics
conditions associated
derived diagnostics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16845218.3A
Other languages
English (en)
French (fr)
Other versions
EP3346912A1 (de
Inventor
Zachary APTE
Jessica RICHMAN
Daniel Almonacid
Siavosh Rezvan BEHBAHANI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Psomagen Inc
Original Assignee
uBiome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by uBiome Inc filed Critical uBiome Inc
Publication of EP3346912A1 publication Critical patent/EP3346912A1/de
Publication of EP3346912A4 publication Critical patent/EP3346912A4/de
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Public Health (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Databases & Information Systems (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Primary Health Care (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Software Systems (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Wood Science & Technology (AREA)
  • Evolutionary Computation (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Social Psychology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
EP16845218.3A 2015-09-09 2016-09-09 Verfahren und system für mikrobiom-derivierte diagnostika und therapeutika für erkrankungen im zusammenhang mit zerebro-kraniofazialer gesundheit Pending EP3346912A4 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562215939P 2015-09-09 2015-09-09
US201562216028P 2015-09-09 2015-09-09
US201562216016P 2015-09-09 2015-09-09
US201562216042P 2015-09-09 2015-09-09
US201562216035P 2015-09-09 2015-09-09
PCT/US2016/051155 WO2017044885A1 (en) 2015-09-09 2016-09-09 Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with cerebro-craniofacial health

Publications (2)

Publication Number Publication Date
EP3346912A1 EP3346912A1 (de) 2018-07-18
EP3346912A4 true EP3346912A4 (de) 2019-08-21

Family

ID=58240338

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16845218.3A Pending EP3346912A4 (de) 2015-09-09 2016-09-09 Verfahren und system für mikrobiom-derivierte diagnostika und therapeutika für erkrankungen im zusammenhang mit zerebro-kraniofazialer gesundheit

Country Status (5)

Country Link
EP (1) EP3346912A4 (de)
CN (1) CN108348167B (de)
AU (1) AU2016321333A1 (de)
CA (1) CA3006044A1 (de)
WO (1) WO2017044885A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3209803A4 (de) 2014-10-21 2018-06-13 Ubiome, Inc. Verfahren und zusammensetzungen für mikrobiom-diagnostika und -therapeutika
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
WO2018094376A1 (en) * 2016-11-21 2018-05-24 uBiome, Inc. Method and system for characterizing a headache-related condition
EP3769321A1 (de) * 2017-06-02 2021-01-27 Psomagen, Inc. Verfahren und system zur charakterisierung von mit mikroorganismen verbundenen schlafbezogenen zuständen
US11154240B2 (en) 2019-04-02 2021-10-26 Kpn Innovations Llc Methods and systems for utilizing diagnostics for informed vibrant constitutional guidance
US12176108B2 (en) 2020-06-02 2024-12-24 Kpn Innovations Llc Artificial intelligence methods and systems for constitutional analysis using objective functions
US11289206B2 (en) 2020-06-02 2022-03-29 Kpn Innovations, Llc. Artificial intelligence methods and systems for constitutional analysis using objective functions
US11211158B1 (en) 2020-08-31 2021-12-28 Kpn Innovations, Llc. System and method for representing an arranged list of provider aliment possibilities
CN113096818B (zh) * 2021-04-21 2023-05-30 西安电子科技大学 基于ode和grud的急性病症发生几率的评估方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013176774A1 (en) * 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
US20140301995A1 (en) * 2011-10-12 2014-10-09 Gut Guide Oy Raising and Diagnosing of Serotonin Level
WO2014179965A1 (en) * 2013-05-09 2014-11-13 The Procter & Gamble Company Biomarker identifying method and system
US20150211078A1 (en) * 2014-01-25 2015-07-30 uBiome, Inc. Method and system for microbiome analysis
WO2016065075A1 (en) * 2014-10-21 2016-04-28 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US20160232280A1 (en) * 2014-10-21 2016-08-11 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060228721A1 (en) * 2005-04-12 2006-10-12 Leamon John H Methods for determining sequence variants using ultra-deep sequencing
EP2201134B1 (de) * 2007-09-19 2018-11-21 The Research Foundation of State University of New York Genexpressionssignaturen in angereicherten tumorzellproben
EP3699296A1 (de) * 2008-11-07 2020-08-26 Adaptive Biotechnologies Corporation Verfahren zur überwachung von zuständen durch sequenzanalyse
US20120149584A1 (en) * 2009-08-21 2012-06-14 Bernat Olle Methods of diagnosing and treating microbiome-associated disease using interaction network parameters
KR102042253B1 (ko) * 2010-05-25 2019-11-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ｂａｍｂａｍ：고처리율 서열분석 데이터의 병렬 비교 분석
US20130230856A1 (en) * 2010-10-27 2013-09-05 Quantibact A/S Capture of target dna and rna by probes comprising intercalator molecules
WO2012103337A2 (en) * 2011-01-26 2012-08-02 The Brigham And Women's Hospital, Inc. Assays and methods to sequence microbes directly from immune complexes
AU2012225310B2 (en) * 2011-03-09 2017-08-03 Cell Signaling Technology, Inc. Methods and reagents for creating monoclonal antibodies
US20130121968A1 (en) * 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
WO2013142378A1 (en) * 2012-03-17 2013-09-26 The Regents Of The University Of California Fast diagnosis and personalized treatments for acne
CN103374518B (zh) * 2012-04-12 2018-03-27 维里纳塔健康公司 拷贝数变异的检测和分类
CN108018343B (zh) * 2012-05-10 2023-01-03 通用医疗公司 用于测定核苷酸序列的方法
RS59199B1 (sr) * 2012-05-25 2019-10-31 Univ California Metode i jedinjenja za rnk-upravljanu ciljanu dnk modifikaciju i za rnk- upravljanu modulaciju transkripta
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
CN104540962B (zh) * 2012-08-01 2017-09-19 深圳华大基因研究院 糖尿病生物标志物及其应用
WO2014121298A2 (en) * 2013-02-04 2014-08-07 Seres Health, Inc. Methods of populating a gastrointestinal tract
WO2014165810A2 (en) * 2013-04-05 2014-10-09 Akins Robert A Systems and methods to assess microbiomes and treatments thereof
WO2015074054A1 (en) * 2013-11-18 2015-05-21 The Trustees Of Columbia University In The City Of New York Improving microbial fitness in the mammalian gut
CN104195145B (zh) * 2014-07-15 2017-01-18 浙江大学 肝硬化的生物标志物及其应用
US10265009B2 (en) * 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140301995A1 (en) * 2011-10-12 2014-10-09 Gut Guide Oy Raising and Diagnosing of Serotonin Level
WO2013176774A1 (en) * 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
WO2014179965A1 (en) * 2013-05-09 2014-11-13 The Procter & Gamble Company Biomarker identifying method and system
US20150211078A1 (en) * 2014-01-25 2015-07-30 uBiome, Inc. Method and system for microbiome analysis
WO2016065075A1 (en) * 2014-10-21 2016-04-28 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US20160232280A1 (en) * 2014-10-21 2016-08-11 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017044885A1 *

Also Published As

Publication number Publication date
AU2016321333A1 (en) 2018-04-26
WO2017044885A1 (en) 2017-03-16
EP3346912A1 (de) 2018-07-18
CN108348167A (zh) 2018-07-31
CA3006044A1 (en) 2017-03-16
CN108348167B (zh) 2022-06-03

Similar Documents

Publication Publication Date Title
EP3347495A4 (de) Verfahren und system für mikrobiomderivierte diagnostika und therapeutika für erkrankungen im zusammenhang mit der magen-darm-gesundheit
EP3209803A4 (de) Verfahren und zusammensetzungen für mikrobiom-diagnostika und -therapeutika
EP3347496A4 (de) Verfahren und system für mikrobiomderivierte diagnostika und therapeutika für die mundgesundheit
EP3317428A4 (de) Verfahren und systeme für diagnostische tests
EP3346912A4 (de) Verfahren und system für mikrobiom-derivierte diagnostika und therapeutika für erkrankungen im zusammenhang mit zerebro-kraniofazialer gesundheit
EP3187112A4 (de) Statisches echtzeit-ct-bildgebungssystem und steuerungsverfahren für bildgebung
EP3090416A4 (de) Verfahren und system zur überwachung
EP3283086A4 (de) Verfahren und system für mikrobiom-derivierte diagnostika und therapeutika für erkrankungen im zusammenhang mit mikrobiom-funktionseigenschaften
EP3299918A4 (de) System zur diagnose von anomalien und verfahren zur diagnose von anomalien
EP3229093A4 (de) Anomaliendiagnoseverfahren und anomaliendiagnosesystem
EP3327402A4 (de) Inspektionssystem und inspektionsverfahren
EP3273648A4 (de) System und verfahren
EP3270096A4 (de) Messsystem, messverfahren und messprogramm
EP3105965A4 (de) System und verfahren zum rehoming von verbindungen
EP3111700A4 (de) System und verfahren zum benutzergerätespezifischen offloading
EP3283084A4 (de) Verfahren und system zur mikrobiomderivierten charakterisierung, diagnostika und therapeutika für hauterkrankungen
EP3270097A4 (de) Messsystem, messverfahren und messprogramm
EP3283649A4 (de) Verfahren und system für mikrobiomabgeleitete charakterisierung, diagnostika und therapeutika für kardiovaskuläre krankheitszustände
EP3283652A4 (de) Verfahren und system für mikrobiomderivierte diagnostika und therapeutika für psychische erkrankungen
GB201510480D0 (en) System and method
IL230969A0 (en) A network-based system and method for influence
EP3347494A4 (de) Verfahren und system für mikrobiomabgeleitete diagnostika und therapeutika für erkrankungen im zusammenhang mit schilddrüsengesundheitsproblemen
EP3120162A4 (de) System und verfahren zur durchführung einer transformatordiagnose
GB201510000D0 (en) System and method
EP3335380A4 (de) Verfahren und system für transaktionsdiagnostik

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180406

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G16B 20/00 20190101ALI20190410BHEP

Ipc: G16B 40/20 20190101ALI20190410BHEP

Ipc: C12Q 1/68 20180101ALI20190410BHEP

Ipc: G16H 50/20 20180101AFI20190410BHEP

Ipc: G16H 50/70 20180101ALI20190410BHEP

Ipc: A61B 5/00 20060101ALI20190410BHEP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61B0005000000

Ipc: G16H0050200000

A4 Supplementary search report drawn up and despatched

Effective date: 20190718

RIC1 Information provided on ipc code assigned before grant

Ipc: A61B 5/00 20060101ALI20190712BHEP

Ipc: C12Q 1/68 20180101ALI20190712BHEP

Ipc: G16H 50/70 20180101ALI20190712BHEP

Ipc: G16B 20/00 20190101ALI20190712BHEP

Ipc: G16B 40/20 20190101ALI20190712BHEP

Ipc: G16H 50/20 20180101AFI20190712BHEP

19U Interruption of proceedings before grant

Effective date: 20191011

19W Proceedings resumed before grant after interruption of proceedings

Effective date: 20201201

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PSOMAGEN, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231122